



AAA NEWS BRIEF – MAY 2008

HIV/AIDS Prevention: “VANHIVAX and HIV/AIDS”

Learn About African Action on AIDS (AAA)

AAA is a tax exempt non-profit organization registered in the USA and operating under section 501(c) 3 of the IRS code. It is also registered in Cameroon (auth. No 00174/A/MINAT/DAP/SDLP/SAC). It has special consultative status with the United Nations ECOSOC and the UN Department of Information.

AAA Mission Statement

We believe that no one is alone. We succeed when the youth we serve become agents of their own change and use their knowledge to change their communities.

We reach the youth of sub-saharan Africa whose lives are affected by AIDS.

We affirm that tomorrow’s responsible parents are the knowledgeable youth of today.

We educate youth with the knowledge they need to stay alive, and teach them to share that knowledge with their peers

We build extended family support networks in local villages and communities to deliver security, food, education and healthcare to children orphaned by AIDS.

We create healthcare awareness by funding women and children’s health.

AAA’s work is based on 3 programmes:

“JUST KNOW” Campaign emphasizes

- Knowledge of one’s body
- Knowledge that leads to behaviour change
- Knowledge that helps to visualize a future without AIDS

“Health before Wealth” Concept promotes

- Safe potable water and sanitation (wells, latrines, hand washing stations in schools)
- Income generating activities (IGA) -- treated mosquito nets and Sur’Eau – a liquid that purifies water) to create a fund for women’s health in rural areas.

“Women’s economic autonomy” through our **Scholarships Programme**. This scholarship enables each teenage orphan girl to complete at least a secondary, general or technical education that will lead to her financial and economic autonomy, greatly reducing the risk of being infected with HIV through sexual abuse and violence.

Contacts:

USA	Europe	Cameroon
Ruth Bamela Engo <i>President</i> African Action on AIDS 511 Avenue of the Americas #302 New York, NY 10011, USA E-Mail: ruthengo@aol.com	Herta P. Kaschitz <i>AAA Representative in Vienna</i> Schottenfeldgasse 20/9 1070 Vienna, Austria E-Mail: hpkaschitz@aol.com	Theodore L. Tangie <i>Chief, AAA Yaoundé Office</i> B.P. 4340, Yaoundé Cameroon E-Mail: longtchi@yahoo.com

www.africanactiononids.org

“VANHIVAX and HIV/AIDS”

Our work consisted in understanding the structure of HIV, correctly interpreting the function of its various parts and in finding solutions to various problems raised by these parts. The envelope of HIV is of CD4+ or human origin and the virus must have acquired it in the course of its evolution! The presence of the envelope of human origin on HIV leads to 3 major consequences:-

a) Ineffective antibodies to the virus in the body. If they were indeed effective, they would kill the virus, as well as all the CD4+ - a kind of suicide unacceptable to the body! The virus has thus used its envelope to ‘blackmail’ the body’s immune system into ineffectiveness, thus guarantee its continued existence in the body. **b)** CD4+ and other cells are normally impenetrable to all antibodies. In wrapping itself in CD4+ membrane, HIV not only wishes to pass off for a normal CD4+ cell but above all it wants the same security of cells of being impenetrable to all antibodies. **c)** HIV grows within the CD4+ and because the CD4+ loses its cell wall membrane as envelopes to the thousands of mature viruses that leave it, these helper cells die leading to a fall of the patient’s immunity rendering him open to a host of opportunistic infections. (Hepatitis B & C and other viruses also have envelopes of human origin for their prolonged survival in the body).

Based on this understanding, we have produced VANHIVAX from the patient’s virus which is effective and given to the patient to provoke a cell mediated immune response which alone penetrates the viral envelope. Patients should, of course, be immune competent with low viral count and high CD4+. Of the many patients treated with VANHIVAX, 18 of them, the tip of the iceberg, have converted to sero-negative and are no longer infective. They were seen early in their infection with an immune competent system. Most AIDS patients who came late with depressed immunity were greatly helped by VANHIVAX but could not achieve sero-negativity. Their immunity must first be raised before a curative vaccination with VANHIVAX can be prescribed. If VANHIVAX is prepared from viruses grown in a region of the world and used in the same manner, it can prevent the spread of HIV infection in that region. With the simultaneous application of the simple technology of VANHIVAX in different parts of the world, this epidemic could soon be brought under control.

Professor Victor Anomah Ngu

Former Minister of Public Health, Cameroon / Founder of Clinique de l’Espoir / Member of the International Advisory Board of AAA

AAA & Partners’ Activities in the field

HAPPY INTERNATIONAL LABOUR DAY!

